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Seizures in children are one of the most fearful experiences for parents and caretakers. Epilepsy is defined according to the International League Against Epilepsy as “A disease of 
the brain defined by any of the following conditions: (a) At least 
two unprovoked (or reflex) seizures occurring >24 h apart, (b) 
one unprovoked (or reflex) seizure and a probability of further 
seizures similar to the general recurrence risk (at least 60%) after 
two unprovoked seizures, occurring over the next 10 years, and 
(c) diagnosis of an epilepsy syndrome” [1]. The prevalence of 
pediatric epilepsy in India is 5.35/1000 [2]. In children, less than 
5 years, the most common cause of seizure is febrile seizures, of 
which more than 12% are prolonged lasting more than half an 
hour [3]. Seizures are one of the most common occurrences in 
pediatric emergency department.
Intravenous access is not always possible for emergency 
anticonvulsant treatment for children having a seizure, and an 
effective and safe alternative which can be useful in all settings 
including peripheral health centers, homes, and schools is warranted. 
Conventionally, diazepam is given rectally [4] or parentally, but 
IV lorazepam is being followed as the first-line drug in most of 
the centers. For IV administration in a convulsing child, special 
arrangement is required along with skilled personals, which is not an 
easy task in schools, day-care centers and even in some health-care 
centers. An effective treatment that can be easily administered by a 
more convenient and socially acceptable route is therefore needed.
More recently, the intranasal [5] or buccal route for midazolam 
has come up as a safe and effective alternative. Buccal midazolam [6] 
is effective, but it can be less reliable as it is often practically difficult 
to insert the liquid between cheek and teeth while the child is actively 
convulsing and when large doses are needed. Pharmacokinetic data 
(rapid action and bioavailability) [7] and acceptability to patients 
indicate that intranasal midazolam is a suitable alternative, and it is 
easy to administer the drug into the nasal cavity [8].
In this context, the present study was undertaken to compare 
the efficacy and safety of intranasal midazolam with IV lorazepam 
(which is the standard treatment) in the treatment of acute and 
prolonged seizures in children.
MATERIALS AND METHODS
An interventional study was conducted among the children with 
acute seizures in the pediatric emergency department of a tertiary 
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hospital in South India. Ethical committee and Institutional 
scientific committee clearance were obtained before the study. 
The period of study was 1 year.
Children aged 6 months–12 years with tonic/clonic/tonic-
clonic seizures who have not received any medication for the 
present event from any other hospital/home and whose parents/
guardians gave consent to participate were included in the 
study. Children with absence seizures, atonic seizures, and non-
conclusive seizures or patients who had come after receiving any 
anticonvulsive medication for the present event were excluded.
The sample size was determined to be 80 (40 patients in each 
group).
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Sample size calculated from the mean time for seizure control 
by both drugs.
Group 1 patients were administered intranasal midazolam while 
Group 2 patients were administered IV lorazepam. After emergency 
management and stabilization of the airway and breathing, aqueous 
midazolam 0.2 mg/kg was administered intranasally through 
automated aqueous intranasal spray (Midacip 0.5 mg per puff) in 
lying down or in 45degree propped up position to Group 1, while 
injectable lorazepam 0.1 mg/kg was administered intravenously (to 
a maximum of 4 mg) to Group 2. Continuous monitoring of vitals 
(heart rate, respiratory rate, and partial pressure of O2 [SPO2]) was 
done until the patient was stabilized and shifted to the ward/intensive 
care unit (ICU). The duration from the time of arrival of the patient 
to the control of seizures was noted.
Data collection was done by the patient’s father, mother, or 
the guardian after stabilization of the patient on a predesigned 
pro forma. Pre designed pro forma was document with the details 
collected from the parents or guardian of the patient after they are 
stabilized. The treatment was considered ‘successful’ if seizures 
ceased within 5 min; ‘successful but delayed’ if seizures ceased 
in 5-10min and ‘treatment failure’ if seizures were not controlled 
within 10 min of drug administration. If not controlled within 10 
min, the patient was managed as per hospital protocols.
Qualitative data were analyzed using proportion, and 
quantitative data with mean and other statistical analysis were 
used depending on nature of data. Covariates between two groups 
(midazolam and lorazepam) were compared by Chi-square test, 
Fisher’s exact test, or Student’s t-test, and p<0.05 was taken as 
statistically significant.
RESULTS
Total patients in the study were 80 (40 in each group). The analysis 
of data shows that both the groups were comparable in baseline 
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characteristics such as age distribution and gender distribution. 
Some comparisons are charted below (Table 1).
The duration of seizure as on reaching the hospital emergency 
department was varying, hospital emergency department was 
varying. So they were categorized as < 10min and >15min. There 
was a statistically significant correlation between IV lorazepam 
and intranasal midazolam groups in <10 min and >15 min group 
(p=0.0123, 0.0123, respectively).
The success rate of controlling seizures which lasted for more 
than 15 min was better with intranasal midazolam compared to 
IV lorazepam (p=0.0003). In case of seizures lasted for more than 
30 min, both the drugs were equally effective. Seizure control 
was not achieved in 10 (25%) subjects of lorazepam group and 9 
(22.5%) subjects of midazolam group and their difference was not 
statistically significant (p=0.635).
All the subjects were monitored for respiratory depression 
signs (respiratory rate, heart rates, and SpO2) for half an hour, 
before shifting to the ward/ICU. None of the patients in both the 
groups had respiratory depression.
Mean time to administer drug after arrival in the intranasal 
midazolam group (mean 3.65 min standard deviation [SD] 1.167 
[0.955–1.498]) when compared to the IV lorazepam group (mean 
7.93 min SD 3.23 [2.645–4.147]) was statistically significant 
(p=0.0001). The mean time to control the seizure after arrival of 
patient in the intranasal midazolam group (mean 12.05 min SD 
12.327 [10.091–15.828]) when compared to the IV lorazepam group 
(mean 15.28 min SD 10.879 [8.911–13.969]), p value - 0.218. The 
time taken to control the seizures after the drug was administered in 
the intranasal midazolam group (mean 2.55 min SD 1.915 [1.568–
2.458]) when compared to the IV lorazepam group (mean 2.87 min 
SD 1.915 [1.568–2.458]); p value - 0.481 (Table 2).
DISCUSSION
In the present study, we compared the efficacy, duration, and safety 
of intranasal midazolam to IV lorazepam (which is considered an 
effective first-line drug in acute seizure management [9]. Other 
studies comparing IV lorazepam with intranasal midazolam are 
not available. In our observation, intranasal midazolam is equally 
effective as IV lorazepam.
In the present study, seizure control among children with 
intranasal midazolam was 77.5% which is comparable with other 
studies and had no incidence of respiratory depression. Harbord 
et al. [5] used intranasal midazolam to treat acute seizures in 
pediatric community settings and showed good seizure control 
of 89%, without any safety issues or difficulty in administering 
Table 1: Comparison of some of the profile characteristics
Profile characteristics Lorazepam (n=40) Midazolam (n=40) Chi‑square p value
Male/Female 20 (50%)/20 (50%) 21 (52.5%)/19 (47.5%) 0.05 0.823
Afebrile seizures 25 (62.5%) 26 (65%) 0.05 0.81
Previous status epileptics 9 (22.5%) 10 (25%) 0.06 0.792
H/O missed drugs 6 (15%) 2 (5%) 2.2 0.136
Developmental delay 3 (7.5%) 7 (17.5%) 1.8 0.176
Family h/o epilepsy 8 (20%) 3 (7.5%) 2.63 0.104
Hypocalcemia 1 (2.5%) 2 (5%) 0.34 0.554
Seizure type:
Generalized 39 (97.5%) 34 (85%)
3.913 0.047*
Focal 1 (2.5%) 6 (15%)
*p<0.05; significant
Table 2: Time taken for administration of drug and seizure control
Time taken to administer drug from the time 
of arrival
<3 mins < 5 mins < 10 mins <15 mins
IV lorazepam 1 15 33 40
Intranasal midazolam 19 40 - -
p value 0.0001* 0.0006* 0.159 0.0001*
Time taken to control seizure from the time of 
arrival
<3 min <5 min <10 min <15 min Uncontrolled
IV lorazepam 0 01 23 24# 10
Intranasal midazolam 04 14 29 31 09
p value 0.123 0.0006* 0.241 0.147 0.792
Time to control seizure after drugs administered <1 min <5 min <10 min Uncontrolled
IV lorazepam 0 27 30 10
Intranasal midazolam 09 28 31 09
p value 0.004* 0.809 0.798 0.792
#There were 6 cases in which time taken to control seizure from the time of arrival was more than 15 min but was controlled within 10 minutes of drug administration. *p<0.05; 
significant
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the drug. Fisgin et al. [10], Bhattacharyya et al. [11], and Lahat 
et al. [12] compared intranasal midazolam to rectal diazepam 
in which the midazolam aborted seizures in 87%, 96.7%, and 
88%, respectively, and found to be safe. In the present study, IV 
LORAZEPAM had 75% seizure control, which is comparable 
with Arya et al. [13] study which was found to be 80%.
Some of the added advantages in the usage of intranasal midazolam 
over IV lorazepam were the shorter duration taken to administer 
intranasal midazolam and its fast action after administration.
The mean time for administration of the drug from the time 
of arrival of the patient was significantly less in the intranasal 
midazolam group when compared with the IV lorazepam group 
(p=0.0001) in the present study. The mean time was 3.65 min (SD 
1.167), 95% confidence interval 0.955–1.498 in the intranasal 
midazolam group, which is comparable with Lahat et al. [12] 
study where the mean time was 3.5 min (SD 1.8), 95% confidence 
interval 3.3–3.7. In the IV lorazepam group, the mean time of 
administration of the drug after arrival of the patient was 7.93 min 
(SD 3.23), 95% confidence interval 2.645–4.147. This was longer 
than the Arya et al. study [13] where this time was 4 min.
We also found that intranasal midazolam group, the drug could 
be rapidly administered (i.e. 47.5% of patients received the drug 
within 3 min and the rest 52.5% within 5 min) than IV lorazepam 
group (where only 37.5% received by 5 min and it took up to 
15 min for all the patients to receive the drug) (p<0.05).
The mean time for controlling seizure after arrival of the patient 
in the present study was 12.05 minutes in the intranasal midazolam 
group, which was less than the IV lorazepam group (15.28 min). 
The difference is not statistically significant (p=0.218). Panchal 
et al. [14] studied the duration of intranasal midazolam is shorter 
(3.380 min/SD - 1.19). In the present study, on subdividing the time 
taken in each group, we found that 35% of patients in the intranasal 
midazolam group had significant control of seizures within <5 min, 
while only 2.5% of patients could be controlled in the IV lorazepam 
group, which was statistically significant (p=0.0006).
There was no overall significant difference between the two 
groups in the time taken to control the seizures after the drug was 
administered. In the present study, the mean time taken was 2.55 min 
(SD 1.915) 95% confidence interval 1.568–2.458, in the intranasal 
midazolam group, and it is comparable with Bhattacharyya et al. 
[11] study where the mean time was 1.945–2.115 minutes. In the 
IV lorazepam group, the mean time to control seizures from drug 
administration was 2.87 min (SD 1.929) 95% confidence interval 
1.580–2.476, which was comparable with Arya et al. [13] study 
where the time taken varied from 1 to 36 min (median 3 min) 
and also with Lissauer et al. study, where seizures stopped within 
10 min in 83% of cases [15]. In the present study, we could find 
statistically significant control of seizures within 1 minute of 
administration in intranasal midazolam group in 22.5% of patients, 
while 0% of patients got controlled in the IV lorazepam group 
(p=0.004). This is comparable with the Conroy et al. [16] study 
with intranasal midazolam where 15% responded within 1 min. 
Hence, intranasal midazolam can be considered to be as effective as 
IV lorazepam. Simultaneously, EEG recording has not been done 
to prove the seizure cessation which is a limitation of this study.
CONCLUSION
The efficacy and safety of intranasal midazolam is comparable 
with that of IV lorazepam in treating in children in the age 
group 6 months–12 years. The ease to administer, effective and 
rapid action without any respiratory depression makes intranasal 
midazolam a promising first-line drug for acute seizures in 
peripheral settings or at home/day-care centers, and in tertiary 
centers, patients where IV access are difficult or delayed due to 
various reasons.
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